- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02641769
Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.
Intra-Testicular Transplantation of Purified Autologous Clusters of Differentiation (CD) 34+,133+, and Mesenchymal Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Non-obstructive azoospermia (NOA) is generally considered a non-medically manageable cause of male infertility. These patients, who constitute up to 10% of all infertile men, have abnormal spermatogenesis as the cause of their azoospermia. The etiology affecting approximately 60% of azoospermic men, includes non-obstructive causes of azoospermia, including toxic exposures or abnormal testicular development. NOA results from either primary testicular failure (elevated Luteinizing Hormone (LH), Follicle stimulating hormone (FSH), small testes affecting up to 10% of men presenting with infertility), secondary testicular failure (congenital hypogonadotropic hypogonadism with decreased LH and FSH, small testes), or incomplete or ambiguous testicular failure (either increased FSH and normal volume testes, normal FSH and small testes, or normal FSH and normal testis volume). Prior to microsurgical testicular sperm retrieval techniques and IVF/ICSI, donor insemination was the only option available to men with NOA. The establishment of in vitro fertilization using intracytoplasmic sperm injection (ICSI) as a standard treatment modality has resulted in a number of these men successfully fathering a child through surgically retrieved sperm from the testis. The challenge, however, is to improve their spermatogenic function to enable the appearance of sperm in their ejaculate or to improve the chances of a successful retrieval from the testis for ICSI.
The initial evaluation aims at resolving the following issues: (1) confirming azoospermia, (2) differentiating obstructive from non-obstructive etiology, (3) assessing for the presence of reversible factors and (4) evaluating for the presence of genetic abnormalities. An elevated follicle-stimulating hormone (FSH) level or an absence of normal spermatogenesis by testicular histology in the presence of azoospermia is generally considered sufficient evidence of a non-obstructive etiology. The most common reversible factors that need to be ruled out include recent exogenous hormone administration, severe febrile illnesses, chemotherapy/radiation or prolonged antibiotic use.
During past few years a considerable progress in the derivation of male germ cells from pluripotent stem cells has been made. These studies provide a desirable experimental model for elucidating underlying molecular mechanism of male germ cell development and potential strategies for producing haploid germ cells for the treatment of male infertility. Spermatogenesis is a complex process by which spermatogonial stem cells (SSC) self-renew and differentiate into haploid spermatozoa. In mammals, this process takes place in the seminiferous tubules of testis, which provide a functional niche for male germ cells and involve three major stages: mitosis, meiosis, and spermiogenesis. Errors at any stage of spermatogenesis can result in subfertility and infertility.
Researchers are currently developing alternative treatment options for these men involving stem cells. It has been verified that mouse induced pluripotent stem cells (iPSCs) can form functional spermatozoa. Functional assays have shown that spermatozoa generated from iPSCs were capable of fertilizing the oocytes after intracytoplasmatic injection and giving rise to fertile offspring following embryo transfer. So far, functional male gametes from human iPSCs have not been obtained.
There are two possible approaches in generating of male germ cells from pluripotent stem cells: in vitro differentiation into advanced, haploid cell products or combined in vitro differentiation and in vivo transplantation. However, the originality of this study is illustrated in the transplantation of purified autologous CD34+/CD133+ and mesenchymal bone marrow stem cells (BMSCs) into infertile patients without in vitro breeding, culture, or manipulation thus avoiding in vitro cell propagation risks as genetic mutations and DNA changes. The cells are withdrawn and injected back into the patient on the very same day of the procedure, hence conferring the highest safety and efficacy parameters.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Adeeb AlZoubi, PhD
- Phone Number: 00962795337575
- Email: adeebalzoubi@stemcellsarabia.net
Study Locations
-
-
-
Amman, Jordan, 11953
- Recruiting
- Stem Cells of Arabia
-
Contact:
- Adeeb AlZoubi, PhD
- Phone Number: 00962795337575
- Email: adeebalzoubi@stemcellsarabia.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Infertile males with confirmed diagnosis of non-obstructive azoospermia (NOA)
Exclusion Criteria:
- Patients with Obstructive Azoospermia (OA)
- Previous surgical history in Testis
- Patients with infectious genital diseases
- Patients with anatomical abnormalities of the genital tract
- Patients with major medical problems as malignancies
- Chromosomal aberration (e.g. Y microdeletion, trisomy….)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Stem Cell Transplantation
intervention with transplantation of autologous purified stem cells
|
intervention with transplantation of autologous purified stem cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Appearance of different germ cells in testicles through the progress of spermatogenesis will be assessed by the count of cells using histological studies.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
General improvements of testicular morphology will be assessed with histological studies.
Time Frame: 12 months
|
12 months
|
Improvement in sexual function will be assessed using a questionnaire
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Adeeb AlZoubi, PhD, Stem Cells of Arabia
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCA-INF1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-obstructive Azoospermia
-
Istituto Clinico HumanitasCompletedObstetric Complication | Non-obstructive Azoospermia | Obstructive Azoospermia
-
Mount Sinai Hospital, CanadaMcGill University; Canadian Institutes of Health Research (CIHR); Weill Medical... and other collaboratorsUnknownNon-obstructive AzoospermiaUnited States, Canada
-
Herlev and Gentofte HospitalUniversity of Michigan; Rigshospitalet, Denmark; Holbaek Sygehus; Skane University...CompletedNon-obstructive AzoospermiaDenmark, Sweden
-
Assiut UniversityUnknown
-
NYU Langone HealthWithdrawnInfertility | Non-obstructive Azoospermia | VasectomyUnited States
-
Cairo UniversityCompletedNon Obstructive AzoospermiaEgypt
-
University Hospital, Clermont-FerrandCompletedNon-obstructive Azoospermia With Testicular Biopsy for Spermatozoa ExtractionFrance
-
Cairo UniversityRecruiting
-
Peking University Third HospitalCompletedNon-obstructive AzoospermiaChina
-
University of Illinois at ChicagoWithdrawnHypogonadism | Non Obstructive AzoospermiaSpain
Clinical Trials on Stem Cell Transplantation
-
Northwestern UniversityTerminated
-
National Heart Institute, MexicoNational Center of Blood Transfusion Mexico.UnknownAcute Myocardial InfarctionMexico
-
General Hospital of Chinese Armed Police ForcesWithdrawn
-
Wake Forest University Health SciencesCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...WithdrawnAnemia | Thrombocytopenia | Neutropenia | Hematopoietic/Lymphoid Cancer | Lymphopenia
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of
-
Daping Hospital and the Research Institute of Surgery...Children's Hospital of Chongqing Medical University; Chongqing Maternal and...Withdrawn
-
Royan InstituteCompletedCerebral PalsyIran, Islamic Republic of
-
Children's Hospital of Chongqing Medical UniversityUnknownBronchopulmonary DysplasiaChina
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of